NASDAQ:VNDA

Vanda Pharmaceuticals (VNDA) Stock Forecast, Price & News

$4.51

+0.05 (+1.12%)

(As of 09/22/2023 ET)

Compare

Today's Range: $4.28
▼
$4.57
50-Day Range: $4.28
▼
$6.53
52-Week Range: $4.15
▼
$11.04

Volume: 1.21 million shs
Average Volume: 2.22 million shs
Market Capitalization: $259.37 million

P/E Ratio: 16.70
Dividend Yield: N/A
Price Target: N/A

Vanda Pharmaceuticals MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
5.04% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.77
Upright™ Environmental Score
News Sentiment: 1.77
Based on 2 Articles This Week
Insider Trading: Selling Shares
$75,009 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

214th out of 963 stocks

Pharmaceutical Preparations Industry

84th out of 455 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Vanda Pharmaceuticals.

2.0

Short Interest

Percentage of Shares Shorted
5.04% of the float of Vanda Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vanda Pharmaceuticals has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Vanda Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Vanda Pharmaceuticals does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Vanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.
Environmental Sustainability
The Environmental Impact score for Vanda Pharmaceuticals is -1.77.

4.3

News and Social Media Coverage

News Sentiment
Vanda Pharmaceuticals has a news sentiment score of 1.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Vanda Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
4 people have searched for VNDA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
4 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vanda Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $75,009.00 in company stock.
Percentage Held by Insiders
Only 7.70% of the stock of Vanda Pharmaceuticals is held by insiders.
Percentage Held by Institutions
97.92% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Vanda Pharmaceuticals is 16.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.54.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vanda Pharmaceuticals is 16.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.99.
Price to Book Value per Share Ratio
Vanda Pharmaceuticals has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vanda Pharmaceuticals (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

VNDA Price History

30 days | 90 days | 365 days | Advanced Chart

VNDA Stock News Headlines

September 22, 2023 | stocknews.com

Bionano Genomics (BNGO) Challengers: 3 Biotech Innovators to Buy Instead

September 5, 2023 | finance.yahoo.com

Why Shares of Vanda Pharmaceuticals Are Dropping on Tuesday

September 24, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

September 1, 2023 | finance.yahoo.com

5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects

September 1, 2023 | finance.yahoo.com

After Plunging -7.98% in 4 Weeks, Here's Why the Trend Might Reverse for Vanda (VNDA)

August 17, 2023 | fool.com

Vanda Pharmaceuticals (NASDAQ: VNDA)

August 1, 2023 | finance.yahoo.com

Earnings growth of 9.4% over 5 years hasn't been enough to translate into positive returns for Vanda Pharmaceuticals (NASDAQ:VNDA) shareholders

July 28, 2023 | finanznachrichten.de

Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results

September 24, 2023 | Stansberry Research (Ad)

Are "The Magnificent Seven" the Next Sears?

The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.

July 28, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results

July 28, 2023 | finance.yahoo.com

Q2 2023 Vanda Pharmaceuticals Inc Earnings Call

July 27, 2023 | markets.businessinsider.com

What Wall Street expects from Vanda Pharmaceuticals's earnings

July 25, 2023 | thestreet.com

Vanda's Hetlioz Is Starting to Sell -- Slowly -- After Bumbling Through the Pipeline

July 20, 2023 | finance.yahoo.com

Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023

June 5, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference

June 2, 2023 | msn.com

Vanda gains on FDA orphan drug designation for nerve disorder candidate

June 1, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

June 1, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Announces Presentations at SLEEP 2023

May 30, 2023 | bizjournals.com

Vanda Pharmaceuticals eyeing ‘path forward’ for motion sickness treatment

May 25, 2023 | finance.yahoo.com

A Sea Change in Motion Sickness Therapy: Vanda Pharmaceuticals' Tradipitant Shows Promising Data in Real-world Test

May 25, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness

May 24, 2023 | entrepreneur.com

4 Best Biotech Stocks According to POWR Ratings

May 10, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal

May 4, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Announces Presentations at DDW 2023

May 4, 2023 | finance.yahoo.com

Q1 2023 Vanda Pharmaceuticals Inc Earnings Call

May 3, 2023 | reuters.com

Vanda Pharmaceuticals sues US over drug-trade secrets

May 3, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results

See More Headlines

Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VNDA Company Calendar

Last Earnings: 7/27/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:VNDA
CUSIP: 92165910
CIK: 1347178
Web: www.vandapharma.com
Phone: (202) 734-3400
Fax: 202-296-1450
Employees: 290
Year Founded: 2002

Profitability

EPS (Most Recent Fiscal Year): $0.27
Trailing P/E Ratio: 16.70
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $6.28 million
Net Margins: 6.25%
Pretax Margin: 9.73%
Return on Equity: 2.81%
Return on Assets: 2.34%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.10
Quick Ratio: 6.09

Sales & Book Value

Annual Sales: $254.38 million
Price / Sales: 1.02
Cash Flow: $0.11 per share
Price / Cash Flow: 42.22
Book Value: $9.32 per share
Price / Book: 0.48

Miscellaneous

Outstanding Shares: 57,510,000
Free Float: 53,081,000
Market Cap: $259.37 million
Optionable: Optionable
Beta: 0.70

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Mihael H. Polymeropoulos M.D. (Age 63)
Founder, Pres, CEO & Chairman of The Board
Comp: $1.51M

Mr. Kevin Patrick Moran (Age 39)
Sr. VP, CFO & Treasurer
Comp: $660.22k

Mr. Timothy Williams (Age 47)
Sr. VP, Gen. Counsel & Sec.
Comp: $724.38k

Mr. Joakim Wijkstrom (Age 57)
Sr. VP & Chief Marketing Officer
Comp: $836.36k

Mr. Gunther Birznieks (Age 53)
Sr. VP of Bus. Devel.
Comp: $690.83k

Mr. Scott L. Howell
Chief People Officer

Ms. Elizabeth Van Every
Head of Corp. Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VNDA Stock - Frequently Asked Questions

How have VNDA shares performed in 2023?: Vanda Pharmaceuticals' stock was trading at $7.39 on January 1st, 2023. Since then, VNDA shares have decreased by 39.0% and is now trading at $4.51.
View the best growth stocks for 2023 here.
When is Vanda Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our VNDA earnings forecast.
How were Vanda Pharmaceuticals' earnings last quarter?: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its quarterly earnings data on Thursday, July, 27th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.16. The biopharmaceutical company had revenue of $46.06 million for the quarter, compared to analysts' expectations of $49 million. Vanda Pharmaceuticals had a net margin of 6.25% and a trailing twelve-month return on equity of 2.81%.
What ETFs hold Vanda Pharmaceuticals' stock?: ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Horizon Kinetics Medical ETF (MEDX), iShares Neuroscience and Healthcare ETF (IBRN), iShares U.S. Pharmaceuticals ETF (IHE),
What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?: 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Vanda Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

What is Vanda Pharmaceuticals' stock symbol?: Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."
Who are Vanda Pharmaceuticals' major shareholders?: Vanda Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (18.80%), State Street Corp (7.10%), Renaissance Technologies LLC (5.41%), Goldman Sachs Group Inc. (3.66%), Dimensional Fund Advisors LP (3.39%) and Hotchkis & Wiley Capital Management LLC (2.18%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams.
View institutional ownership trends.
How do I buy shares of Vanda Pharmaceuticals?: Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vanda Pharmaceuticals' stock price today?: One share of VNDA stock can currently be purchased for approximately $4.51.
How much money does Vanda Pharmaceuticals make?: Vanda Pharmaceuticals (NASDAQ:VNDA) has a market capitalization of $259.37 million and generates $254.38 million in revenue each year. The biopharmaceutical company earns $6.28 million in net income (profit) each year or $0.27 on an earnings per share basis.
How many employees does Vanda Pharmaceuticals have?: The company employs 290 workers across the globe.
How can I contact Vanda Pharmaceuticals?: Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The official website for the company is www.vandapharma.com. The biopharmaceutical company can be reached via phone at (202) 734-3400, via email at pr@vandapharma.com, or via fax at 202-296-1450.

This page (NASDAQ:VNDA) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial